Economics of hematopoietic cell transplantation.
Given the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalization, to $200 000 (USD) or more for a myeloablative allogeneic procedure involving an unrelated donor. Common posttransplantation complications, such as infections and GVHD, have been shown to be significant cost drivers. Comparisons across studies are limited by differences in patient populations, cost ascertainment methods, and length of follow-up. This article summarizes the current state of knowledge about costs and cost-effectiveness of HCT, highlighting the challenges in conducting these studies and identifying important areas for future research. We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate.
Division of Hematology/Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA. khera.nandita@mayo.edu
Nandita
N
Khera
Steven B
SB
Zeliadt
Stephanie J
SJ
Lee
D003362:Cost-Benefit Analysis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000191:economics*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics; D019172:Transplantation Conditioning / Q000191:economics; D014182:Transplantation, Autologous / Q000191:economics; D061349:Unrelated Donors
D004364:Pharmaceutical Preparations